Levamisole-induced leukoencephalopathy: a rare drug side effect
https://doi.org/10.20862/0042-4676-2024-105-6-314-324
Abstract
Levamisole is an antihelminthic drug that is widely used in clinical practice. One of its rare side effects is the development of levamisole-associated multifocal inflammatory leukoencephalopathy, which progresses 2–8 weeks after treatment and is characterized by brain demyelination and white matter damage. The article describes a case of levamisole-induced leukoencephalopathy, which should be differentiated from multiple sclerosis, acute disseminated encephalomyelitis, and neuromyelitis optica.
Keywords
levamisole,
levamisole-induced leukoencephalopathy,
levamisole-associated multifocal inflammatory leukoencephalopathy
Supporting agencies: The authors express their gratitude to the staff of Department of Computed Tomography and Magnetic Resonance Imaging, Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, as well as to the editors of the journal for the opportunity to publish the results of their work.
About the Authors
E. S. Yelshibayeva
Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan; Astana Medical University
Kazakhstan
Kazakhstan
Elmira S. Yelshibayeva, PhD, Head of the Department of Computed Tomography and Magnetic Resonance Imaging; Associate Professor
prospekt Mangilik El, 80, Astana, 010000
ul. Beibytshilyk, 49/А, Astana, 010000
A. Zh. Suigenbayev
Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan
Kazakhstan
Kazakhstan
Aigerim Zh. Suigenbayeva, Radiologist
prospekt Mangilik El, 80, Astana, 010000
A. B. Mergalimova
Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan
Kazakhstan
Kazakhstan
Akerke B. Mergalimova, Resident Radiologist
prospekt Mangilik El, 80, Astana, 010000
Zh. B. Ospanova
Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan
Kazakhstan
Kazakhstan
Zhanar B. Ospanova, Neurologist
prospekt Mangilik El, 80, Astana, 010000
References
1. Howelland M, Prevenier W. From reliable sources: an introduction to historical methods. Cornell University Press; 2001: 77 pp.
2. Thompson JS, Herbick JM, Klassen LW, et al. Studies on levamisole-induced agranulocytosis. Blood. 1980; 56(3): 388–96.
3. Scheinfeld N, Rosenberg JD, Weinberg JM. Levamisole in dermatology: a review. Am J Clin Dermatol. 2004; 5(2): 97–104. https://doi.org/10.2165/00128071-200405020-00004.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med. 1990; 322(6): 352–8. https://doi.org/10.1056/NEJM199002083220602.
5. Wolford A, McDonald TS, Eng H, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos. 2012; 40(6): 1067–75. https://doi.org/10.1124/dmd.112.045021.
6. Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol. 1999; 140(5): 948–51. https://doi.org/10.1046/j.1365-2133.1999.02833.x.
7. Karch SB, Mari F, Bartolini V, Bertol E. Aminorex poisoning in cocaine abusers. Int J Cardiol. 2012; 158(3): 344–6. https://doi.org/10.1016/j.ijcard.2011.06.105.
8. WHO model list of essential medicines – 21st list, 2019. Available at: https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06 (accessed 03.11.2024).
9. Campillo JT, Eiden C, Boussinesq M, et al. Adverse reactions with levamisole vary according to its indications and misuse: a systematic pharmacovigilance study. Br J Clin Pharmacol. 2022; 88(3): 1094–106. https://doi.org/10.1111/bcp.15037.
10. Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol. 2012; 50(4): 231–41. https://doi.org/10.3109/15563650.2012.665455.
11. Midthun KM, Nelson LS, Logan BK. Levamisole – a toxic adulterant in illicit drug preparations: a review. Ther Drug Monit. 2021; 43(2): 221−8. https://doi.org/10.1097/FTD.851.
12. Zakharova M, Zakroyshchikova I, Kozlova A, et al. Levamisole-induced leukoencephalopathy in Russia: analysis of 30 cases. Curr Drug Saf. 2022; 17(4): 319–26. https://doi.org/10.2174/1574886317666211224121517.
13. Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol. 2017; 91(6): 2303–13. https://doi.org/10.1007/s00204-017-1947-4.
14. Wu VC, Huang JW, Lien HC, et al. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine. 2006; 85(4): 203–13. https://doi.org/10.1097/01.md.0000230250.95281.60.
15. Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992; 31(3): 262–7. https://doi.org/10.1002/ana.410310306.
16. Fassas AB, Gattani AM, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest. 1994; 12(4): 379–83. https://doi.org/10.3109/07357909409038226.
17. Kimmel DW, Wijdicks EF, Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology. 1995; 45(2): 374–6. https://doi.org/10.1212/wnl.45.2.374.
18. Luppi G, Zoboli A, Barbieri F, et al. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Ann Oncol. 1996; 7(4): 412–5. https://doi.org/10.1093/oxfordjournals.annonc.a010610.
19. Liu HM, Hsieh WJ, Yang CC, et al. Leukoencephalopathy induced by levamisole alone for the treatment of recurrent aphthous ulcers. Neurology. 2006; 67(6): 1065–7. https://doi.org/10.1212/01.wnl.0000237344.06122.79.
20. Xu N, Zhou W, Li S, et al. Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J Neuroimaging. 2009; 19(4): 326–31. https://doi.org/10.1111/j.1552-6569.2008.00344.x.
21. Figueredo AT, Fawcet SE, Molloy DW, et al. Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Cancer Invest. 1995; 13(6): 608–11. https://doi.org/10.3109/07357909509024930.
22. Cossaart N, SantaCruz KS, Preston D, et al. Fatal chemotherapy-induced encephalopathy following highdose therapy for metastatic breast cancer: a case report and review of the literature. Bone Marrow Transpl. 2003; 31(1): 57–60. https://doi.org/10.1038/sj.bmt.1703768.
23. Chastel C, Mabin D. Encephalopathies after levamisole therapy. Neurology. 1996; 46(1): 288. https://doi.org/10.1212/wnl.46.1.288.
24. Zheng R. Differential diagnosis of delayed encephalopathy induced by anthelmintic imidazoles. Zhonghua Nei Ke Za Zhi. 1995; 34(7): 468–71 (in Chinese).
25. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M. 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Exp Neurol. 1997; 147(1): 123–9. https://doi.org/10.1006/exnr.1997.6598.
26. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.
27. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013; 84(8): 909–14. https://doi.org/10.1136/jnnp-2012-304695.
Review
For citations:
Yelshibayeva E.S., Suigenbayev A.Zh., Mergalimova A.B., Ospanova Zh.B. Levamisole-induced leukoencephalopathy: a rare drug side effect. Journal of radiology and nuclear medicine. 2024;105(6):314-324. (In Russ.) https://doi.org/10.20862/0042-4676-2024-105-6-314-324
Views:
135
Email this article 